文献速递医学人工智能与信息学真实世界研究与卫生经济

基于人工智能的阿片类药物使用障碍风险筛查在住院成人中的临床实施

Clinical implementation of AI-based screening for risk for opioid use disorder in hospitalized adults.
PubMed 文献 · Nat Med · 2025-04-03

这项前后对照准实验研究评估嵌入电子健康记录的AI驱动阿片类药物使用障碍筛查工具,在识别患者接受成瘾医学咨询方面是否不劣于常规诊疗。咨询完成比例在干预期前后无显著变化(1.35% vs 1.51%,非劣效性P < 0.001)。二次分析中,AI筛查与30天再入院减少相关(比值比0.53,95%置信区间0.30-0.91,P = 0.02),每避免一次再入院增量成本为6801美元。

要点

  • AI筛查工具嵌入电子健康记录,实时分析记录识别阿片类药物使用障碍风险患者并推荐咨询。
  • 咨询完成比例干预期前后分别为1.51%和1.35%,非劣效性P < 0.001。
  • AI筛查与30天再入院减少相关,比值比0.53(95%置信区间0.30-0.91,P = 0.02)。

核心结论

  • AI驱动的阿片类药物使用障碍筛查工具在识别患者接受成瘾医学咨询方面不劣于常规诊疗,并可能作为可扩展且具成本效益的解决方案。

研究设计与样本

  • 前后对照准实验研究,研究期包括16个月干预前阶段和8个月干预后阶段,期间实施AI筛查工具支持医院提供者识别需咨询患者。
  • AI筛查工具使用卷积神经网络实时分析电子健康记录记录,识别风险患者并推荐咨询。

主要发现

  • 主要结局咨询完成比例干预期前后分别为1.51%和1.35%,非劣效性P < 0.001。
  • 二次分析中,AI筛查与30天再入院减少相关,比值比0.53(95%置信区间0.30-0.91,P = 0.02)。
  • 每避免一次再入院的增量成本为6801美元。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Adults with opioid use disorder (OUD) are at increased risk for opioid-related complications and repeated hospital admissions. Routine screening for patients at risk for an OUD to prevent complications is not standard practice in many hospitals, leading to missed opportunities for intervention. The adoption of electronic health records (EHRs) and advancements in artificial intelligence (AI) offer a scalable approach to systematically identify at-risk patients for evidence-based care. This pre-post quasi-experimental study evaluated whether an AI-driven OUD screener embedded in the EHR was non-inferior to usual care in identifying patients for addiction medicine consultations, aiming to provide a similarly effective but more scalable alternative to human-led ad hoc consultations. The AI screener used a convolutional neural network to analyze EHR notes in real time, identifying patients at risk and recommending consultations. The primary outcome was the proportion of patients who completed a consultation with an addiction medicine specialist, which included interventions such as outpatient treatment referral, management of complicated withdrawal, medication management for OUD and harm reduction services. The study period consisted of a 16-month pre-intervention phase followed by an 8-month post-intervention phase, during which the AI screener was implemented to support hospital providers in identifying patients for consultation. Consultations did not change between periods (1.35% versus 1.51%, P < 0.001 for non-inferiority). In secondary outcome analysis, the AI screener was associated with a reduction in 30-day readmissions (odds ratio: 0.53, 95% confidence interval: 0.30-0.91, P = 0.02) with an incremental cost of US$6,801 per readmission avoided, demonstrating its potential as a scalable, cost-effective solution for OUD care. ClinicalTrials.gov registration: NCT05745480 .

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Afshar M, Resnik F, Joyce C, et al. Clinical implementation of AI-based screening for risk for opioid use disorder in hospitalized adults. Nat Med. 2025. PMID: 40181180. doi:10.1038/s41591-025-03603-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。